FSSAI files 3 cases against Nestlé India over infant-formula claims
FSSAI has initiated three adjudication cases involving promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, plus an alleged biotin-quality issue in a follow-up formula. Nestlé India says its products and labels comply with applicable regulations.
What happened
FSSAI has filed three adjudication cases against Nestlé India over promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, and alleged substandard
Key facts
- 3 adjudication cases
- 5 HMOs
- Regulation 4(2), Foods for Infant Nutrition Regulations, 2020
- Section 3, IMS Act, 1992
Why this matters
Any infant-nutrition partnership, acquisition or distribution diligence should deepen review of claims substantiation, labeling controls and product-quality compliance following the FSSAI actions against Nestlé India.
What to watch
- FSSAI adjudication notices specifying alleged violations, proposed penalties, corrective actions, or product-testing findings.
- Any direction to modify labels, stop promotions, withdraw batches, or issue public notices.
- Publication of laboratory results or details on the alleged biotin-quality issue, including whether it concerns safety, nutrient specification, or documentation.
- Nestlé India changes to product pages, packaging, advertisements, or healthcare-professional communications.
- Retailer actions such as delisting, warning labels, reduced visibility, or increased requests for compliance certificates.
- Additional FSSAI scrutiny of other Nestlé infant-nutrition products or parallel enforcement against category competitors.
- Parent-sentiment deterioration, complaint volumes, social-media amplification, and market-share movement in premium infant nutrition.
- Conduct a portfolio-wide legal and scientific substantiation audit of infant-formula labels, digital content, healthcare-professional materials, and retailer listings.
- Temporarily suspend or narrow potentially contested claim language on NAN Excella Pro Stage 1 and Lactogen Pro 1 while cases proceed.
- Increase batch-level quality documentation and independent testing visibility for the affected follow-up formula and related products.
- Prepare pediatrician, distributor, retailer, and consumer communications emphasizing product safety, regulatory compliance, and any label changes.
- Model downside from promotional disruption, potential penalties, inventory relabeling, and retailer delisting risk; preserve supply flexibility for SKU substitutions.